News

Institutional Investors Expand Tesla Stakes

Finance

Institutional Investors Expand Tesla Stakes

7 sourcesUpdated Oct 19, 20261 min read

0

Institutional Investors Expand Tesla Stakes — © IJR

Sponsored

Several investment firms reported new or increased positions in Tesla during the third quarter, including St. Louis Financial Planners Asset Management, TD Waterhouse Canada, AlphaStar Capital Management, TB Alternative Assets and Cornerstone Wealth Advisors. The filings add to other institutional buying reported in the articles, while institutional investors collectively held about 66.2% of Tesla shares. Analyst views cited in one report were mixed, ranging from a raised buy rating to hold and market-perform ratings.

Sponsored

In this story:

More on this story

Back to News

Business

Anthropic IPO Valuation Could Reach $1.5 Trillion

Anthropic’s planned IPO is facing mounting uncertainty as investors reportedly push to lower its expected valuation from roughly $1.4 trillion–$1.5 trillion, with estimates ranging toward $1 trillion to $1.3 trillion amid a sell-off in AI stocks. Prediction-market odds for a near-term listing have also fallen, and reports say the company could reduce the offering or delay it.

426 sources

Sports

Miller, Varland Win Inaugural BBWAA Reliever Awards

Total sources

7

Last updatedOct 19, 2026

Does this breakdown look right?

Sponsored

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

Padres closer Mason Miller and Blue Jays closer Louis Varland won the inaugural BBWAA Reliever of the Year awards for their leagues. Miller led the NL with 38 saves and posted a 1.67 ERA, while Varland recorded 35 saves and a 1.27 ERA for Toronto.

18 sources

Sponsored

Health

Blackstone backs Pfizer obesity drug with $1.5B

Blackstone will provide up to $1.5 billion through 2028 to help Pfizer develop berobenatide, an experimental monthly GLP-1 drug for weight management and obesity-related conditions. Pfizer retains ownership and control, while Blackstone could receive milestone payments if the drug wins U.S. approval and reaches specified sales targets.

9 sources